昂妥昔珠單抗(INN:Ontuxizumab[1])是一種人源化兔單株抗體,[2]設計用於治療癌症。它與內皮唾液酸蛋白(也稱TEM1或CD248)結合。[3]該藥物的I期試驗已經完成,該藥物被美國食品藥品監督管理局授予治療肉瘤的孤兒藥地位。目前正處於黑色素瘤、結直腸癌、肉瘤和淋巴瘤的II期試驗中。[4]
該藥物由Morphotek和路德維希癌症研究所開發。[4]
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109 (PDF). WHO Drug Information. 2013, 27 (2) [2024-01-23]. (原始內容存檔 (PDF)於2022-01-20).
- ^ US 20100260769,Sass PM, Kline B, Nicolaides N, Grasso L, Harley S,「Endosialin binding molecules」,發表於2010-04-08,指定於Morphotek Inc
- ^ Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, et al. Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment. August 2015, 8 (2): 111–8. PMC 4542822
. PMID 26085332. doi:10.1007/s12307-015-0168-8.
- ^ 4.0 4.1 Ontuxizumab. Adis Insight. Springer Nature Switzerland AG. [2024-01-23]. (原始內容存檔於2024-01-23).